Abstract
Fragment-Based Drug Discovery (FBDD) is a strategy to develop potent lead molecules and is frequently used in drug discovery projects of the pharmaceutical industry. This method starts from identifying a small-molecule fragment, which usually binds weakly to the target and follows with a hit-to-lead step in which the fragment is grown into potent molecules that bind tightly to the target to affect its function. Quite a few drugs and compounds in clinical trials are developed using this approach, making FBDD a powerful strategy in drug discovery. FBDD can be applied to multiple targets and the hit rate in screening can be used in target druggability assessment. In this minireview, we provide a summary of the development of FBDD. In addition to giving a brief summary of the methods used in fragment screening, we highlight some methods that are critical in fragment growth. Biophysical methods and careful chemical modification of the fragments are the key elements in FBDD. We show several strategies that can be utilized in FBDD. We emphasize that NMR spectroscopy such as 19F-NMR and 1H-15N-HSQC experiment and X-ray crystallography are important in FBDD due to their roles in fragment screening and understanding the binding modes of the fragment hits, which provides a strategy for fragment growth.
Keywords: Fragment-based drug discovery, Structural biology, Hit identification, Fragment growth, Druggability, NMR, Biophysics, X-ray crystallography.
Current Topics in Medicinal Chemistry
Title:Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets
Volume: 21 Issue: 13
Author(s): Qingxin Li*Congbao Kang*
Affiliation:
- Guangdong Provincial Engineering Laboratory of Biomass High Value Utilization, Institute of Biological and Medical Engineering, Guangdong Academy of Sciences, Guangzhou 510316,China
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, Chromos, #05-01, Singapore 138670,Singapore
Keywords: Fragment-based drug discovery, Structural biology, Hit identification, Fragment growth, Druggability, NMR, Biophysics, X-ray crystallography.
Abstract: Fragment-Based Drug Discovery (FBDD) is a strategy to develop potent lead molecules and is frequently used in drug discovery projects of the pharmaceutical industry. This method starts from identifying a small-molecule fragment, which usually binds weakly to the target and follows with a hit-to-lead step in which the fragment is grown into potent molecules that bind tightly to the target to affect its function. Quite a few drugs and compounds in clinical trials are developed using this approach, making FBDD a powerful strategy in drug discovery. FBDD can be applied to multiple targets and the hit rate in screening can be used in target druggability assessment. In this minireview, we provide a summary of the development of FBDD. In addition to giving a brief summary of the methods used in fragment screening, we highlight some methods that are critical in fragment growth. Biophysical methods and careful chemical modification of the fragments are the key elements in FBDD. We show several strategies that can be utilized in FBDD. We emphasize that NMR spectroscopy such as 19F-NMR and 1H-15N-HSQC experiment and X-ray crystallography are important in FBDD due to their roles in fragment screening and understanding the binding modes of the fragment hits, which provides a strategy for fragment growth.
Export Options
About this article
Cite this article as:
Li Qingxin*, Kang Congbao *, Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets, Current Topics in Medicinal Chemistry 2021; 21 (13) . https://dx.doi.org/10.2174/1568026621666210804115700
DOI https://dx.doi.org/10.2174/1568026621666210804115700 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Receptor Specific Macrophage Targeting by Mannose-Conjugated Gelatin Nanoparticles- An In Vitro and In Vivo Study
Current Nanoscience Glutamate and Schizophrenia
Current Neuropharmacology Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences The Epidemiological and Pangenome Landscape of <i>Staphylococcus aureus</i> and Identification of Conserved Novel Candidate Vaccine Antigens
Current Proteomics Morpholine Based Diazenyl Chalcones: Synthesis, Antimicrobial Screening and Cytotoxicity Study
Anti-Cancer Agents in Medicinal Chemistry An Approach for the Rational Design of New Antituberculosis Agents
Current Drug Targets Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design The Seattle Structural Genomics Center for Infectious Disease (SSGCID)
Infectious Disorders - Drug Targets Design, Synthesis and Antitubercular Evaluation of New 2-amino-5-(4- (benzyloxy)benzyl)thiophene-3-carboxylic Acid Derivatives. Part 3
Letters in Drug Design & Discovery Virtual Screening, Docking, Synthesis and Bioactivity Evaluation of Thiazolidinediones as Potential PPARγ Partial Agonists for Preparation of Antidiabetic Agents
Letters in Drug Design & Discovery Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design Pseudomonas aeruginosa Cif Defines a Distinct Class of α/β Epoxide Hydrolases Utilizing a His/Tyr Ring-Opening Pair
Protein & Peptide Letters Novel, Unifying Phagomimetic Mechanism of Vancomycin Therapeutic Action and Toxicity: Polyphenol, Electron Transfer and Reactive Oxygen Species
Anti-Infective Agents in Medicinal Chemistry Response to HAART in Treatment-Naive HIV-Infected Patients with a Prior Diagnosis of Tuberculosis or other Opportunistic Infections
Current HIV Research Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis
Current Drug Targets Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Current Pharmaceutical Design Nanoemulsion-Based Transdermal Drug Delivery System for the Treatment of Tuberculosis
Recent Patents on Anti-Infective Drug Discovery